Oncotelic recently reverse merged with Mateon (OTCQB:MATN). The combined company is the leader in TGF-β therapeutics and is dedicated to the development of first in class in self-immunization protocol (SIP©) as a durable cure for difficult to treat cancers. This therapeutic cancer vaccine has broad-spectrum applicability for multiple cancer types and does not require extraction of the tumor and isolation of the antigen for immunization- a lengthy/laborious process with limited clinical effectiveness. It showed promising clinical activity in phase 2 trials for the treatment of gliomas and pancreatic cancers. The founding team of Oncotelic was part of the team who developed Abraxane®. Abraxane® was approved in 2005 and has $1B in sales annually. The team later on led the development and commercialization of Cynviloq®, a next-generation Abraxane. Oncotelic intends to leverage its deep expertise in oncology and RNA therapeutic drug development to the eradication of cancer.
Company HQ State:
Company HQ Country:
Main Therapeutic Focus:
Lead Product in Development:
Development Phase of Primary Product:
Number Of Unlicensed Products (For Which You Are Seeking Partners):